(By Balachander) Emergent Biosolutions Inc. (NYSE: EBS) said it has secured exclusive right to manufacture and sell VaxInnate Corp.'s pandemic influenza vaccine candidate in the United States.
Under a license agreement with VaxInnate, Emergent Biosolutions acquired exclusive U.S. commercial rights to next generation pandemic influenza vaccine candidate.
This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority (BARDA), the company noted.
Emergent said the product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner.
[Related -Another 636% Jump In Sales For This Biotech?]
VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.
Emergent is required to acquire intellectual property rights for a pandemic influenza vaccine candidate and to obtain facility licensure to manufacture a pandemic influenza vaccine under contract HHSO100201200004I, funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services.
EBS shares, which have been trading between $12.50 and $18.34 over the past year, shed 0.31 percent to trade at $15.86 on Friday.